NRXP NRX Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1719406 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,076.5%
TTM net income YoY48.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin40.5%
Operating margin-551.7%
Net margin-454.1%
FCF margin—
EBITDA margin-546.4%
Returns
ROE—
ROA-92.3%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets107.1%
Debt / equity—
Current ratio0.76x
Interest coverage-17.37x
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio17.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.23M | $0 |
| Cost of revenue | $505,000 | $0 |
| Gross profit | $720,000 | $0 |
| R&D expense | $3.78M | $6.20M |
| SG&A expense | $13.06M | $13.50M |
| Operating income | -$16.22M | -$18.50M |
| Interest expense | $671,000 | $230,000 |
| Income tax | $0 | $0 |
| Net income | -$28.62M | -$25.13M |
| EBITDA | -$16.15M | -$18.50M |
| EPS (basic) | -1.34 | -2.36 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $7.80M | $1.44M |
| Receivables | $161,000 | $0 |
| Current assets | $8.89M | $3.30M |
| PP&E, net | $63,000 | $10,000 |
| Goodwill | $1.79M | $0 |
| Intangibles | $925,000 | $0 |
| Total assets | $12.96M | $3.65M |
| Current liabilities | $28.58M | $21.86M |
| Total liabilities | $28.89M | $26.87M |
| Shareholders' equity | -$15.94M | -$23.22M |
| Shares outstanding | 31.73M | 14.59M |
| Cash flow statement | ||
| Operating cash flow | -$14.11M | -$10.64M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$10.64M |
| Investing cash flow | -$2.81M | $0 |
| Financing cash flow | $23.28M | $7.49M |
| Depreciation & amortization | $70,000 | $5,000 |
| Stock-based compensation | $228,000 | $486,000 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.